<div id="readability-page-1" class="page"><div>
    <div>
        <figure id="media-100000005759316" data-media-action="modal" itemprop="associatedMedia" itemscope="" itemid="https://static01.nyt.com/images/2018/02/24/science/24drug1-print/23DRUG1-master768.jpg" itemtype="http://schema.org/ImageObject" aria-label="media" role="group">
    <span>Photo</span>
    <div>
            <img src="https://static01.nyt.com/images/2018/02/24/science/24drug1-print/23DRUG1-master768.jpg" alt="" data-mediaviewer-src="https://static01.nyt.com/images/2018/02/24/science/24drug1-print/23DRUG1-superJumbo.jpg" data-mediaviewer-caption="A Teva Pharmaceutical drug manufacturing facility in Jerusalem. The company announced earlier this month it would sell a generic version of the drug Syprine at a lower price, but it&amp;rsquo;s hardly a bargain." data-mediaviewer-credit="Thomas Koehler/Photothek, via Getty Images" itemprop="url" itemid="https://static01.nyt.com/images/2018/02/24/science/24drug1-print/23DRUG1-master768.jpg">
            <meta itemprop="height" content="512">
            <meta itemprop="width" content="768">
    </div>
        <figcaption itemprop="caption description">
                <span>A Teva Pharmaceutical drug manufacturing facility in Jerusalem. The company announced earlier this month it would sell a generic version of the drug Syprine at a lower price, but it’s hardly a bargain.</span>
                        <span itemprop="copyrightHolder">
            <span>Credit</span>
            Thomas Koehler/Photothek, via Getty Images        </span>
            </figcaption>
    </figure>

<p data-para-count="252" data-total-count="252" _translation="當最近Teva Pharmaceuticals宣布它將開始銷售Syprine仿製藥 - 一種在20世紀60年代發明的昂貴藥物時 - 對於服用價格暴漲的老藥物的人來說，這個消息似乎是一個值得歡迎的發展。">When Teva Pharmaceuticals announced recently that it would begin selling a copycat version of Syprine — an expensive drug invented in the 1960s — the news seemed like a welcome development for people taking old drugs that have skyrocketed in price.</p><p data-para-count="523" data-total-count="775" _translation="在Valeant Pharmaceuticals International將該藥的價格從五年前的652美元提高到2015年的21,267美元之後，Syprine 治療罕見的Wilson病。除了圖靈藥業的Martin Shkreli和Mylan（EpiPen的製造商）的Heather Bresch等醫藥高管的類似做法外，這個故事還引發了關於處方藥高成本的全國對話，更不用說國會調查和聯邦調查了。">Syprine, which treats a rare condition known as Wilson disease, <a href="https://www.nytimes.com/2015/10/05/business/valeants-drug-price-strategy-enriches-it-but-infuriates-patients-and-lawmakers.html">gained notoriety after Valeant Pharmaceuticals International raised the price of the drug</a> to $21,267 in 2015 from $652 just five years earlier. Along with similar practices by pharmaceutical executives like <a href="https://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html?action=click&amp;contentCollection=Business%20Day&amp;module=RelatedCoverage&amp;region=Marginalia&amp;pgtype=article">Martin Shkreli of Turing Pharmaceuticals</a> and <a href="https://www.nytimes.com/2016/08/27/business/painted-as-a-villain-mylans-chief-says-shes-no-such-thing.html">Heather Bresch of Mylan</a> (the maker of the EpiPen), the story helped spark a national conversation about the high cost of prescription drugs, not to mention Congressional inquiries and federal investigations.</p><p data-para-count="195" data-total-count="970" _translation="在推廣其 “Syprine”的“低成本”替代方案時，Teva執行官在新聞稿中吹噓說，該產品“體現了Teva致力於服務有需求的患者群體”。"><a href="http://www.tevapharm.com/news/teva_announces_launch_of_a_generic_version_of_syprine_in_the_united_states_02_18.aspx">In promoting its</a> “lower-cost” alternative to Syprine, a Teva executive boasted in a news release that the product “illustrates Teva’s commitment to serving patient populations in need.”</p><p data-para-count="270" data-total-count="1240" _translation="Elsevier公司的黃金標準藥物數據庫顯示，這款產品沒有提及的價格是：Teva的新型仿製藥每瓶100粒的價格為18,375美元。這是Syprine在2010年花費的28倍，並且幾乎沒有許多病人等待的折扣。">What the release didn’t mention was the price: Teva’s new generic will cost $18,375 for a bottle of 100 pills, <a href="https://www.elsevier.com/solutions/drug-database">according to Elsevier’s Gold Standard Drug Database.</a> That’s 28 times what Syprine cost in 2010, and hardly the discount many patients were waiting for.</p>
<p data-para-count="217" data-total-count="1457" id="story-continues-1" _translation="在Valeant令人震驚的價格上漲引發公眾憤怒之後的近三年，Syprine的故事突出表明，一旦將其價格設定在平流層水平，降低藥品價格有多難。">Nearly three years after Valeant’s egregious price increases ignited public outrage, the story of Syprine highlights just how hard it can be to bring down drug prices once they’ve been set at stratospheric levels.</p>        <a href="#story-continues-2">Continue reading the main story</a>
    </div><!-- close story-body -->
    <!-- close supplemental -->
</div><div>
    <div>
        <p data-para-count="377" data-total-count="1834" id="story-continues-3" _translation="儘管美國食品和藥物管理局為鼓勵沒有通用替代品的藥物爭取更多的競爭，但只要沒有顯著的競爭，像Teva這樣的公司仍然會按市場承受的那樣收費。甚至像Valeant這樣受到嚴厲批評的公司，往往可以通過援助計劃消除消費者的不滿。">Despite efforts by the Food and Drug Administration to encourage more competition for drugs that have no generic alternatives, companies like Teva will still charge as much as the market will bear as long as there is no significant competition. And even companies that come under intense criticism, like Valeant, can often neutralize consumer upset through assistance programs.</p><p data-para-count="195" data-total-count="2029" _translation="雖然這些可以降低患者的自付費用，但這些計劃將保險費用保留在賬單的大部分中，然後通過更高的保費和免賠額將這些費用轉嫁給消費者。">While those can lower out-of-pocket costs for patients, the programs stick insurers with the bulk of the bill, which in turn can be passed on to consumers through higher premiums and deductibles.</p><p data-para-count="192" data-total-count="2221" _translation="現年59歲的Jay Copeland一直服用Syprine十年來治療Wilson病，這種病導致銅在體內積聚，如果不治療會導致器官和神經損傷。">Jay Copeland, 59, has been taking Syprine for a decade to treat Wilson disease, a condition that causes copper to build up in the body, leading to organ and neurological damage if not treated.</p><p data-para-count="361" data-total-count="2582" _translation="“科普蘭先生說，通用價格”令人難以置信的懲罰性“，他說，他的雇主的保險使他免受大部分藥物的損失，但他擔心如果他失去了工作會發生什麼。他表示，Teva稍低的價格“對我來說，如果我能夠支付巨額實付費用，這對我來說幾乎沒有什麼影響。”">Calling the generic price “incredibly punitive,” Mr. Copeland said his employer’s insurance shields him from most of the drug’s cost, but he worries what would happen if he were to lose his job. Teva’s slightly lower price, he said, “would make relatively little difference to me if I were put in the position to pay enormous out-of-pocket costs.”</p><p data-para-count="264" data-total-count="2846" _translation="為了鼓勵更加普遍的競爭，FDA最近公佈了一份非專利藥物清單，該清單沒有競爭並且清除了一般的申請積壓。但正如Syprine案例所顯示的那樣，通常並不像添加一個通用競爭對手那麼簡單。">To encourage more generic competition, the F.D.A. recently published a list of off-patent drugs that have no competition and cleared a backlog of generic applications. But as the Syprine case shows, it often isn’t as simple as adding a single generic competitor.</p><p data-para-count="208" data-total-count="3054" _translation="“總的來說，仿製藥在有多個參與者的情況下工作，”Wells Fargo的分析師David Maris說。他本週撰寫了關於Teva的普通Syprine價格的文章。“如果沒有，你會得到這個。”">“By and large, generics work when there are multiple players,” said David Maris, an analyst at Wells Fargo who wrote this week about Teva’s generic Syprine price. “When there’s not, you get this.”</p><p data-para-count="345" data-total-count="3399" _translation="如果只有少數參與者，並且如同威爾遜病一樣，這些藥物會治療一小部分患者，那麼這些公司將盡可能多地獲得利潤。根據數據調查公司IQVIA的數據，2017年前三個季度僅有5,226張處方藥物用於Syprine，也被稱為鹽酸曲恩汀。">If there are just a few players and if the drug treats a small group of patients, as is the case with Wilson disease, the companies will try to make as much profit as they can. Just 5,226 prescriptions were filled for Syprine, also known as trientine hydrochloride, in the first three quarters of 2017, according to the data research firm IQVIA.</p>
<p data-para-count="255" data-total-count="3654" id="story-continues-4" _translation="根據威爾遜疾病協會科學事務副總裁瑪麗·格雷珀的說法，威爾遜病被認為在美國有8000到10000人之間影響，有些病人服用其他藥物。">Wilson disease is believed to affect between 8,000 and 10,000 people in the United States, and some with the condition take other drugs, according to Mary Graper, the vice president of scientific affairs at the Wilson Disease Association, a patient group.</p><p data-para-count="266" data-total-count="3920" _translation="“通用公司以營利為目的的公司，也和讓他們在定價他們認為市場的承受能力的產品，這並不奇怪我，”亞倫S. Kesselheim博士，哈佛大學醫學院副教授說，誰擁有研究藥物價格。">“Generic companies are for-profit companies, too, and so it’s not surprising to me that they price the product at what they think the market will bear,” said Dr. Aaron S. Kesselheim, an associate professor at Harvard Medical School <a href="http://www.nejm.org/doi/full/10.1056/NEJMc1711899">who has studied </a>drug prices.</p><figure id="media-100000005759318" data-media-action="modal" itemprop="associatedMedia" itemscope="" itemid="https://static01.nyt.com/images/2018/02/23/science/23DRUG2/23DRUG2-master675.jpg" itemtype="http://schema.org/ImageObject" aria-label="media" role="group">
    <span>Photo</span>
    <div>
            <img src="https://static01.nyt.com/images/2018/02/23/science/23DRUG2/23DRUG2-master675.jpg" alt="" data-mediaviewer-src="https://static01.nyt.com/images/2018/02/23/science/23DRUG2/23DRUG2-superJumbo.jpg" data-mediaviewer-caption="J. Michael Pearson, center, the chief executive of Valeant Pharmaceuticals International, at a senate hearing in April 2016. Valeant gained notoriety after raising the price of the drug Syprine from $652 to more than $21,000." data-mediaviewer-credit="Drew Angerer for The New York Times" itemprop="url" itemid="https://static01.nyt.com/images/2018/02/23/science/23DRUG2/23DRUG2-master675.jpg">
            <meta itemprop="height" content="450">
            <meta itemprop="width" content="675">
    </div>
        <figcaption itemprop="caption description">
                <span>J. Michael Pearson, center, the chief executive of Valeant Pharmaceuticals International, at a senate hearing in April 2016. Valeant gained notoriety after raising the price of the drug Syprine from $652 to more than $21,000.</span>
                        <span itemprop="copyrightHolder">
            <span>Credit</span>
            Drew Angerer for The New York Times        </span>
            </figcaption>
    </figure>
<p data-para-count="239" data-total-count="4159" _translation="Teva的一位發言人拒絕評論它如何設定價格，但表示公司考慮了一系列因素。“如果有更多的競爭和充足的供應，定價將繼續下降，”發言人Kaelan Hollon說。">A spokeswoman for Teva declined to comment on how it set its price, but said the company considers a range of factors. “If there is more competition and ample supply, pricing will continue to fall,” said the spokeswoman, Kaelan Hollon.</p><p data-para-count="350" data-total-count="4509" _translation="自稱為世界領先仿製藥製造商的Teva 公司近年來一直面臨管理混亂，銷售領先名牌藥物的失敗，以及 - 與許多常用仿製藥的價格下降 - 相反。去年12月，它宣布進行重大調整，包括削減25％的勞動力。">Teva, <a href="http://www.tevapharm.com/our_products/generic_products/">which calls itself the world’s leading manufacturer</a> of generic drugs, has struggled in recent years with management turmoil, lost sales of a leading brand-name drug, and — in a twist — <a href="https://www.nytimes.com/2017/08/08/health/generic-drugs-prices-falling.html">with the falling prices of many commonly used generic drugs</a>. <a href="https://www.nytimes.com/2017/12/14/business/dealbook/teva-pharmaceuticals-generic.html">In December, it announced a major reshaping</a>, including cutting 25 percent of its work force.</p><p data-para-count="236" data-total-count="4745" _translation="威爾遜病患者一直在註意普通Syprine的到來，但Teva的聲明令他們吃驚，Graper女士說。“我們不知道該期待什麼，但我個人希望有更多的折扣。”">Patients with Wilson disease had been watching for the arrival of a generic Syprine, but Teva’s announcement took them by surprise, Ms. Graper said. "We had no idea what to expect, but I had personally hoped for more of a discount.”</p>

<p data-para-count="387" data-total-count="5132" _translation="Valeant不甘示弱地跟隨了Teva的舉動，發布了自己的“授權”仿製Syprine。一些名牌製藥商希望與仿製藥製造商直接競爭，而不降低其名牌產品的價格，這是一種常見的策略，一些病人仍然喜歡。根據Elsevier的說法，Valeant授權的仿製藥銷售價格為19,119美元。">Not to be outdone, Valeant followed Teva’s move with the release of its own “authorized” generic of Syprine. It’s a common tactic by brand-name drugmakers who want to compete directly with generic manufacturers without lowering the price of their brand-name product, which some patients continue to prefer. Valeant’s authorized generic sells for $19,119, according to Elsevier.</p><p data-para-count="188" data-total-count="5320" _translation="Valeant發言人Lainie Keller表示，其通用名單價格並未反映該公司與買家談判的折扣，但她不會透露這些折扣。">Lainie Keller, a spokeswoman for Valeant, said the list price for its generic did not reflect discounts the company negotiates with buyers, although she would not disclose those discounts.</p><p data-para-count="243" data-total-count="5563" _translation="她表示，Valeant的耐心援助計劃最近得到了改善，以確保私人保險患者每月只需支付約5美元。沒有保險的人可以免費獲得藥物，只要他們符合一定的收入要求。">She said Valeant’s patient assistance programs have recently been improved to ensure that privately insured patients only pay about $5 a month. Those without insurance can get the medication for free if they meet certain income requirements.</p><p data-para-count="383" data-total-count="5946" _translation="瓦倫坦曾經是華爾街的最愛，通過購買舊的非專利藥物如Syprine，大幅提高價格以及在研發上投入很少而使投資者感到高興。這在2015年發生了變化，當時有人提出這個策略對患者產生的影響，以及該公司的財務實踐及其與郵購藥店的關係。">Valeant was once a Wall Street favorite that kept investors happy by buying up old, off-patent drugs like Syprine, sharply raising their prices, and investing little in research and development. That changed in 2015, when questions were raised about the impact this strategy was having on patients, and about the company’s financial practices and its ties to a mail-order pharmacy.</p>
<p data-para-count="173" data-total-count="6119" id="story-continues-5" _translation="國會和聯邦調查公司的做法隨之而來，導致股票暴跌，行政長官和主要投資者離職。">Congressional and federal investigations into the company’s practices followed, <a href="https://www.nytimes.com/2016/03/22/business/valeant-ackman-pearson-earnings.html">leading to a plummeting stock and the departure of the chief executive</a> and major investors.</p><p data-para-count="265" data-total-count="6384" _translation="Graper女士接受了Valeant和Teva的捐款，確認Valeant的患者援助項目有所改善，因為她的小組成員在參議院之前就公司的價格上漲如何導致他們停止服用藥物作證。">Ms. Graper, whose group accepts donations from Valeant and Teva, confirmed that Valeant’s patient assistance program has improved since <a href="https://www.nytimes.com/2016/04/28/business/valeant-pearson-ackman-hearing-congress-drug-prices.html">members of her group testified before the Senate</a> about how the company’s price increases led them to stop taking their drugs.</p><p data-para-count="251" data-total-count="6635" _translation="這些行業援助計劃本身受到審查 - 包括Valeant管理的計劃 - 因為它們幫助提高了藥品價格的高度適口性，緩解了患者自付的負擔，同時讓保險公司支付了其餘的費用。">Such industry assistance programs have themselves come under scrutiny — <a href="https://democrats-oversight.house.gov/sites/democrats.oversight.house.gov/files/documents/Memo%20on%20Valeant%20Documents0.pdf">including ones run by Valeant</a> — because they have helped make high drug prices more palatable, easing patients’ out-of-pocket burdens while leaving insurers to pay the rest.</p><p data-para-count="180" data-total-count="6815" _translation="Graper女士表示希望，如果其他仿製藥競爭者進入市場，價格將繼續下跌。“我認為我們必須等待，看看這兩個地方在哪裡，”她說。">Ms. Graper expressed hope that if other generic competitors enter the market, the price will continue to fall. “I think we have to wait and see where these two land,” she said.</p><p data-para-count="231" data-total-count="7046" _translation="她和其他人表示，他們感到沮喪的是，儘管國會聽證會，政府調查和政治家的承諾亂七八糟，許多引起初步憤慨的藥物的價格仍然一如既往地高。">She and others said they were frustrated that despite a flurry of Congressional hearings, government investigations and promises by politicians, the price of many of the drugs that stoked the initial outrage remain as high as ever.</p><p data-para-count="236" data-total-count="7282" _translation="除了Syprine外，用於治療嚴重寄生蟲感染的老藥Daraprim在Shkreli先生成為社交媒體惡棍之後兩年內仍然是750美元的一顆藥丸，因為他在價格從13.50美元一夜之間將價格提高。">In addition to Syprine, Daraprim, an old drug used to treat a serious parasitic infection, is still $750 a pill more than two years after Mr. Shkreli <a href="https://www.nytimes.com/2017/06/22/business/dealbook/martin-shkreli-pharma-bro-drug-prices.html">became a social media villain</a> for his role in raising the price overnight from $13.50.</p><p data-para-count="285" data-total-count="7567" _translation="EpiPen的成本是該趨勢的一個例外。為響應EpiPen的價格（每包價格高達600美元），Mylan推出了一種更便宜的授權仿製藥。現在可以在許多藥店以約300美元的價格購買一盒EpiPens 。">The cost of the EpiPen is an exception to the trend. In response to the outcry over the EpiPen’s price, which reached about $600 at its height for a pack of two, <a href="https://www.nytimes.com/2016/08/30/business/mylan-generic-epipen.html">Mylan came out with a cheaper, authorized generic</a>. A pack of EpiPens <a href="https://www.goodrx.com/epipen?gclid=EAIaIQobChMIu5qch8O62QIVVbjACh0QKgxPEAAYASAAEgLTsPD_BwE">can now be bought for about $300 at many pharmacies</a>.</p><p data-para-count="183" data-total-count="7750" _translation="“我本來希望會有一些事情發生，政治家們會採取一些行動，但顯然沒有多少事情發生，”科普蘭先生說。“這全都令人沮喪。”">“I had hoped that something would come of it, that the politicians would take some action, but obviously not much has happened,” Mr. Copeland said. “It’s all disheartening.”</p>        <a href="#whats-next">Continue reading the main story</a>
    </div><!-- close story-body -->
    <!-- close supplemental -->
</div></div>